Related Experiment Video
Updated: Jul 29, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.0K
Automation of a Factor XIII Activity Assay Utilizing a Plasma Blank Measurement
Kristi J Smock1, Karen A Moser2
1Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, UT, USA. Kristi.Smock@aruplab.com.
Methods in Molecular Biology (Clifton, N.J.)
|May 19, 2023
Summary
Accurate Factor XIII (FXIII) testing is crucial for diagnosing bleeding disorders. This study details an automated assay with blank correction to prevent overestimation of FXIII activity.
Area of Science:
- Hematology
- Clinical Chemistry
- Coagulation Science
Background:
- Factor XIII (FXIII) is vital for stabilizing fibrin clots against fibrinolysis.
- FXIII deficiency causes severe bleeding disorders, including intracranial hemorrhage.
- Precise laboratory testing is essential for FXIII deficiency diagnosis and management.
Purpose of the Study:
- To describe the automated performance of a commercial FXIII activity assay.
- To evaluate the importance of blank correction in FXIII activity assays.
- To assess the utility of the BCS XP instrument for FXIII testing.
Main Methods:
- Utilized a commercial FXIII activity assay (Technoclone, Vienna, Austria).
- Implemented automated assay performance on the BCS XP instrument.
- Included plasma blank measurements for FXIII-independent ammonia correction.
Main Results:
- The automated assay with blank correction was successfully implemented.
- Blank correction is critical to avoid overestimation of FXIII activity.
- The BCS XP instrument provides a reliable platform for automated FXIII testing.
Conclusions:
- Automated FXIII activity testing with blank correction is feasible and accurate.
- This method ensures reliable diagnosis and monitoring of FXIII deficiency.
- The described approach enhances clinical laboratory efficiency for coagulation testing.
